This article is more than 5 years old. Information may no longer be current.

VIDEO: Combination therapies may improve response to checkpoint inhibitors

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Mary L. “Nora” Disis, MD, medical oncologist at Seattle Cancer Care Alliance and professor of medicine at University of Washington, spoke with HemOnc Today at the ASCO Annual Meeting about treatment strategies for patients who are not effectively responding to checkpoint inhibitor therapy.

“It’s really incredibly interesting to see all of the biomarkers that are now being discovered to try to identify those patients who are going to respond or not respond to immunotherapy,” Disis said.

Disis and colleagues develop cancer vaccines that specifically stimulate type I T cells, which have the ability to be released by checkpoint inhibitors.

In this video, she also discusses use of the vaccine-targeting protein IGFBP2, as well as avelumab (MSB0010718C; Merck, Pfizer) — an anti–PD-L1 checkpoint inhibitor — in patients with ovarian cancer.

“We think a strategy of taking some of these immunogenic tumors that show some response to checkpoint inhibitors and teaming them up with combination therapies may be able to push more patients over into that category [of those] who are really seeing durable responses with this type of immune therapy,” Disis said.